

Biomedical Innovations and Breakthroughs

Program Guide

Featured Topics:

- 1) Gene therapy
- 2) Immune therapy in oncology and vaccines
- 3) Innovation in antibody drug conjugate
- 4) Biomedical breakthroughs and future opportunities
- 5) Targeted covalent drugs

Biomedical Innovations and Breakthroughs

Date & Time: 9:00 am to 9:00 pm, Saturday, April 30th, 2016

Venue: Sanofi, 153 2nd Ave, Waltham, MA 02451

Parking: Free

Featured Topics:

- 1) Gene therapy
- 2) Immune therapy in oncology and vaccines
- 3) Innovation in antibody drug conjugate
- 4) Biomedical breakthroughs and future opportunities
- 5) Targeted covalent drugs

Admission:

CABA members: Free;

On-site membership enrollment is available:

Dinner reception: \$60, (Student: \$45).

Non-members: \$30;

Regular membership: \$30 (One year);

Lifetime membership: \$200;

Online pre-registration for dinner is required.

Conference Organizing Committee

Chair

Bo Ying

Co-Chairs

Carrie Liu

Li Xing

Wendy Yang

Committee Members

Qingqing Cao

Chaoyang Dai

Jun Han

Jo Lee

Xue Shui

Youxin Zhang

Xiangguo Eric Shi

Yin Chen

Shujia Dai

Jeff Hang

Shiwen Lin

Zhigang Wang

Xiaoyong Zhao

Qinglin Che

Ruiyi Dong

Hao Li

Susan Qu

Zhiyong Yang

Liping Zhou

Zhihong Chen

Ellen Fan

Jeannie Li

Jian Shao

Chunxiao Yu

Zhendong Zhu

AGENDA

09:00 - 10:00 am	Registration / Social and Networking
10:00 - 10:05 am	Opening Remarks, Bo Ying , Ph.D., Conference Chair
10:05 - 10:15 am	Introduction of CABA, Susan Qu , Ph.D., President, CABA
10:15 - 11:00 am	KEYNOTE SPEECH: <i>Providing Patients with Access to the Promise of Gene Therapy: A US Perspective.</i> Adam Koppel , MD, Ph.D., MBA, Executive Vice President and Chief Strategy Officer, Biogen

SESSION I – Immunotherapy: The Holy Grail for Cancer Treatment?

SESSION CHAIR: Bo Ying

11:00 - 11:35 am	<i>Nucleic Acid-Based Therapeutics in Oncology and Immuno-oncology.</i> Stephen Kelsey , MD FRCP FRCPATH, President, Onkaido Therapeutics, A Moderna Venture
11:35 - 12:10 pm	<i>Cancer vaccines: Current Status and Future Directions.</i> Derin Keskin , Ph.D., Research Scientist II, Broad Institute, Instructor, Harvard Medical School/Dana Farber Cancer Institute



LUNCH AND VENDOR SHOW: 12:10 – 01:30 pm (Boxed lunch provided)



LUNCHOEN PRESENTATION

12:45 - 01:15 pm	<i>Outlook of Pharma/CRO industry in China.</i> Jun Wang , Ph.D., Vice President, Shanghai, Medicilon
------------------	--

SESSION II – Innovations in Technology

SESSION CHAIR: Jian Shao

01:30 - 2:05 pm

Innovations in Antibody Drug Conjugate R&D.

Richard Gregory, Ph.D., Executive Vice President and Chief Scientific Officer, Immunogen

02:05 - 02:40 pm

Biotherapeutic Immunogenicity: Opportunities for Biobetters and Innovative Biologics.

Karl Griswold, Ph.D., CEO, Stealth Biologics, Associate Professor at the Thayer School of Engineering at Dartmouth College



COFFEE BREAK AND VENDOR SHOW: 02:40 – 03:15 pm



SESSION III – Trends in Market and Science

SESSION CHAIR: Qingqing Cao

03:15 - 03:50 pm

Platforms, Patients and Possibilities

Richard Soll, Ph.D., Senior Vice President, Wuxi AppTec

03:50 - 04:25 pm

Market Trends for Gene Sequencing, Bioinformatics or Gene Diagnostics.

David Wang, MBA, Group Vice President, Medtronics

04:25 - 05:00 pm

Drive Biopharmaceutical Innovation in and Beyond China,

John Tan, President, Kelun US, Pharmaceutical Research Institute



SOCIAL AND NETWORKING: 05:00 – 06:00 pm (Hors d'oeuvres Provided)



DINNER RECEPTION

06:00 - 06:45 pm

KEYNOTE SPEECH: The Resurgence of Covalent Drugs,
Juswinder Singh, Ph.D., President and Chief Scientific Officer,
Ankaa Therapeutics

06:45 - 07:30 pm

CABA Announcement

07:30 - 09:00 pm

Social and Networking

KEYNOTE SPEAKERS



Adam Koppel, M.D., Ph.D. is Executive Vice President, Strategy and Business Development and Chief Strategy Officer at Biogen, where he has served since May 2014. Previously, he was a managing director at Brookside Capital, the public equity affiliate of Bain Capital, which he joined in 2003. Prior to Brookside Capital, he was an associate principal of the McKinsey Healthcare Practice. Dr. Koppel holds Bachelor and Master of Arts degrees in History and Science from Harvard College and earned an M.D. and Ph.D. in Molecular Neurobiology from the University of Pennsylvania. He also received an M.B.A. from the University of Pennsylvania's Wharton School. Dr. Koppel currently serves on the Board of Directors of PTC Therapeutics. He is also a member of the Board of Directors of Trevena, Inc.



Juswinder Singh Ph.D. is a scientist and entrepreneur. He is a pioneer in the development of a new class of drugs termed targeted covalent drugs and in the area of computer-assisted drug design. This work has formed the basis of multiple drugs for the treatment of cancer and autoimmune disease.

Jus earned his B.Sc. (First class honors) in biochemistry at Sussex University in 1984 and Ph.D. in rational drug design from the University of London in 1988. He has a strong background in drug discovery and has worked at Parke-Davis (1991-1994) and also Biogen (1994-2005). In 2006 he decided to form his own company which was the first to focus on developing the field of targeted covalent drugs. In 2012 the company was acquired by Celgene and is now called Celgene Avilomics Research. Jus was awarded the 2016 George and Christine Sosnovsky Cancer award by the American Chemical Society which aims to recognize outstanding achievements in the elucidation of the chemical and biochemical pathways underlying human cancers, leading to the discovery and development of improved cancer therapeutics. He left Celgene in September 2013 and is working on his new startup Ankaa Therapeutics.

FEATURED SPEAKERS



Steve Kelsey is the president of Onkaido Therapeutics, a wholly-owned subsidiary of Moderna Therapeutics focused on mRNA-based therapies for cancer. He was appointed to this role in July 2014. Prior to Onkaido he held positions as senior VP, new projects at Medivation, executive VP of research and development and CMO at Geron Corporation, and VP of hematology and oncology and exploratory clinical development at Genentech. He is a hematologic oncologist by training and held the position of senior lecturer in hematology at Barts and the London, UK from 1993 to 2000. He received his BSc in pharmacology, MB ChB and MD degrees from the University of Birmingham, UK. He is a fellow of the Royal College of Physicians of London and a fellow of the Royal College of Pathologists (UK).



Derin Keskin is an instructor at Harvard Medical School/Dana Farber Cancer Institute and a Research Scientist II at Broad Institute. He is a T cell immunologist investigating vaccine development against viruses and cancers. He also teaches at Harvard Medical School and Boston University.


Derin graduated from Istanbul University Cerrahpasa Medical School in 1997 and earned his PhD studying IDO inhibition of T cell responses in the laboratory of Andrew Mellor at the Medical College of Georgia. He did his postdoctoral studies in the laboratory of Jack Strominger at Harvard University and later in the Laboratory of Ellis Reinherz at Dana Farber Cancer Institute.

FEATURED SPEAKERS

Rich Gregory joined ImmunoGen as CSO & EVP for Research in January of 2015. In this capacity he provides leadership and direction to the Research organization and is responsible for the generation of development candidates based upon ImmunoGen's Antibody Drug Conjugate technology. Rich received his B.Sc. in Biochemistry from Virginia Tech, his Ph.D. in Biochemistry from UMass, and did his post-doctoral training in cancer genetics at the Worcester Foundation for Experimental Biology. In 1989, Rich joined Genzyme as a scientist in the protein engineering group. At Genzyme, Rich was the project leader for the cystic fibrosis (CF) program, where his group did the seminal work which showed how mutations in CFTR lead to cystic fibrosis. Over the ensuing years Rich held a number of leadership positions at Genzyme, including VP Gene Therapy and Portfolio Leader for the Cardiovascular Disease and Immunology therapeutic areas. In 2003, he was appointed the Head of Research at Genzyme, with responsibility – from discovery to development – for all Genzyme therapeutic areas. Following Sanofi's acquisition of Genzyme in 2011, Rich was appointed Head of the Sanofi-Genzyme R&D Center and in that capacity represented Genzyme R&D within the Sanofi Global R&D organization.



Karl Griswold is the CEO of Stealth Biologics LLC and is a tenured Associate Professor of Bioengineering in the Thayer School of Engineering at Dartmouth. His work in the field of protein engineering has resulted in the development of new tools for protein deimmunization, enhanced microbial production systems, novel strategies for gene library construction, and new approaches to high throughput screening of recombinant protein libraries. He studied as a DOW Foundation Scholar at Texas State University, graduating summa cum laude in 1995. He received his Ph.D. from the University of Texas at Austin in 2005, and completed a postdoctoral fellowship under Professor George Georgiou at the University of Texas. Dr. Griswold's recent honors include a "Teacher of the Year" award from the Thayer School of Engineering and a "Young Investigator Award in Translational Biomedical Engineering" from the Coulter Foundation. He has coauthored more than 40 peer-reviewed articles and has patented inventions relating to both synthetic chemistry and biotechnology. He co-founded and serves as the CEO of the biotechnology startup Stealth Biologics, which has developed proprietary biotherapeutic design and deimmunization platforms that are advancing programs with numerous biopharma partners.




FEATURED SPEAKERS



Richard Soll is Senior Vice President, International Discovery Services Unit (IDSU) at WuXi AppTec and leads the WuXi offices in Cambridge, Massachusetts and in Israel to bring WuXi's comprehensive platform of integrated R&D services closer to innovative companies and entrepreneurs in the world's two leading biotech hubs.

Dr. Soll's contributions to drug discovery and development led to the discovery of the HCV breakthrough therapy Zepatier, the JAK2 inhibitor fedratinib, and more than 10 other clinical stage drugs. Dr. Soll has co-authored more than 100 patents and papers. Dr. Soll serves on the board of the Accelerator and has been an SAB member to biotech companies and advisor to entrepreneurs.

Prior to WuXi, Dr. Soll was CSO and VP of R&D at TargeGen where he led multiple clinical stage R&D programs. Dr. Soll founded the chemistry department at 3-Dimensional Pharmaceuticals as VP of Chemistry. Dr. Soll began his industry career at Wyeth Pharmaceuticals, and was trained as a synthetic chemist at Dartmouth and Harvard.



David Wang currently serves as Vice President of Strategy, Insights and Portfolio Management for Medtronic Corporate. Previously, David was Vice President of Strategy and BD&L for both Surgical Solutions Group and Vascular Therapies. He joined Covidien in 2010 after holding positions of increasing global marketing and strategic responsibility in the Cordis cardiovascular and DePuy neuroscience businesses of Johnson & Johnson. Before joining Johnson & Johnson in 2003, David served in various leadership positions at McKinsey & Company and at the University of Chicago's Biological Sciences Division of Academic Computing in Bioinformatics. David received both his bachelor's degree in biological sciences and Master of Business Administration degree in finance from the University of Chicago.

FEATURED SPEAKERS

John Tan is President of Kelun US Pharmaceutical Research Institute (KUPRI), a subsidiary of Kelun Pharmaceutical Group, that he joined in 2015. Currently Kelun has annual sales over 37B RMB, considered as one of China's top pharmaceutical companies with 30,000 staff members. In 2014, Kelun was ranked the 4th most innovative pharma pipeline in China by Thompson Reuters. KUPRI consists of four functional sectors: biologics drug discovery, small-molecule drug discovery, US generic drug R&D and global business development. In this role, Dr. Tan oversees Kelun's US operation and global BD. Previously Dr. Tan joined Merck & Co in 2001 where he has managed various drug discovery and alliance partner program teams, spanning across areas of oncology, cardiovascular, diabetes, antibiotics, endocrinology, and CNS. Prior to that, he was a research fellow at Memorial Sloan-Kettering Cancer Center in New York. Dr. Tan received a Ph. D. from Columbia University.



Jun Wang, VP of Discovery Biology at Shanghai Medicilon Inc. Before joining Medicilon, Dr. Wang was the VP and Head of Biology at Sundia MediTech. Dr. Wang served at Merck & Co., Inc. for 9 years, leading multiple drug-discovery programs on principles of food-animal growth promotion, infectious diseases, diabetics and cardiovascular diseases. Prior to Merck, Dr. Wang worked at a biotech company in Seattle as the head of biology section and served as an assistant professor in University of Texas Southwestern Medical Center and University of Washington for 5 years. Dr. Wang has been invited by many corresponding author in leading scientific journals. Lately, Dr. Wang has been invited by many organizations including University of Cambridge, Royal Society of Chemistry, and Naito Foundation for presentations on his discovery of novel candidates of antibiotics (Platensimycin and Platencin). Dr. Wang got his BS in biophysics from Fudan University and received his Ph.D. in molecular biology and biochemistry from Kobe University (Japan). He had his post-doc training in the Department of Pharmacology at UT Southwestern Medical Center (Dallas).





Biomedical Innovations and Breakthroughs

-----2016 CABA Annual Conference-----





Chinese-American BioMedical Association (CABA) Organizing Committee
of Boston BioForum 2016 – CABA Annual Conference

Excellence in Innovation

Juswinder Singh, PhD

*In recognition of his innovative and persistent pursuit
of covalent drugs as cancer therapeutics*

April 30, 2016
Waltham, Massachusetts, USA



Chinese-American BioMedical Association (CABA) Organizing Committee
of Boston BioForum 2016 – CABA Annual Conference

Leadership in Community Service

Eric Shi, Qinglin Che, Phil Zhang, Zhihong Chen

*In recognition of their leadership in CABA and the community
of Chinese-American professionals*

April 30, 2016
Waltham, Massachusetts, USA



Chinese-American BioMedical Association (CABA) Organizing Committee
of *Boston BioForum 2016 – CABA Annual Conference*

Dedicated Community Service

Jian Shao, Bo Ying, Jo Lee, Xiaoyong Zhao, Wendy Yang, Yawei Kong

*In recognition of their generous service to CABA and the community
of Chinese-American professionals*

April 30, 2016
Waltham, Massachusetts, USA



CABA's Job Fair will be held concurrently with the Boston BioForum, CABA's 2016 Annual Conference. As CABA's most influential event, the conference attracts hundreds of life sciences professionals, venture capitalists, patent lawyers and highly talented students from the Greater Boston area. The job fair aims to provide a reciprocal opportunity for life sciences professionals and students to network with recruiters and hiring managers from top biotech and pharmaceutical companies.

>> For Employers

There are multiple ways for companies to join the job fair. These include:



*Be sure to secure a place for this premier recruiting event. For sponsorship details, please contact Jeannie Li and Xiaoyong Zhao at jobfair@cabaweb.org.

>> For Job Seekers



This event is FREE to all current CABA members. For others, please register for the Annual Conference online/onsite to attend the job fair.

DON'T sit and wait. Take charge of your career development and join us to network with your next potential employers.



10:00 am - 4:00 pm, Saturday, April 30, 2016



Non-Clinical Statistics Workshop

Other Than Clinical Trial, Where Else Statistics Can Be Applied in the Biotech/pharmaceutical Industry?

May 1st, 2016, 9am -12pm

Sanofi Waltham Site | 153 2nd Ave Waltham, MA



Featured Speakers

Fei Wang

Director, Biostatistics, CQO, Sanofi

Yuefeng Lu

Independent Consultant

Registration Fees

Students and Sponsors	\$75
Individual and non-profit	\$100
Industrial	\$150

Register at www.cabaweb.org (Space is limited)

Who Should Attend?

This workshop is designed for professionals who want to learn statistic methods which can be applied to the nonclinical science areas within the pharmaceutical and biotechnology industries, specifically:

- the Discovery and Translational sciences
- the Safety/Toxicology sciences
- the Chemistry, Manufacturing and Quality Control sciences

Sessions

- Drug Discovery Applications
- Quality and Manufacturing Applications

Chinese-American BioMedical Association

美中生物医药协会

2016-2017 CABA LEADERSHIP TEAM

President

Eric Shi, Ph.D.

Investigator, GSK, Waltham, MA

Chairman of the Board

Shiwen Lin, Ph.D.

Director, PAT&CMC, Agenus, Inc. Lexington, MA

President-Elect (2017-2018)

Kevin Fang, Ph.D.

Sr. Director of Medicinal Chemistry, Sunovion Pharmaceuticals Inc.

Treasurer

Liping Zhou, Ph.D.

Senior Scientist, Ipsen Biosciences.

Vice Presidents

Jian Shao, MBA

CEO, Precidag Inc., Wayland MA

Bo Ying, Ph.D.

Senior Scientist, Onkaido Therapeutics, A Moderna Venture, Cambridge, MA

Zhendong Zhu, Ph.D.

Principal Investigator, Celgene Avilomics Research

General Manager of Public Relations

Qingqing Cao, Ph.D.

Project Manager, Insulet Corp.

General Manager of Operations

Ellen Fan, MSc.

Consultant, Anika Therapeutics

Executive Committee Members

Lan Cao, Ph.D.

Director, Process & Analytical Development, Unum Therapeutics

Yin Chen, Ph.D.

Director of Business Development at Accelagen

Qinglin Che, Ph.D.

Senior Scientist, Tetrphase Pharmaceuticals, Inc.

Henry Gu, J.D.

Assistant General Counsel, IP, ARIAD Pharmaceuticals, Cambridge, MA

Jianfeng Jeff Hang, Ph.D.

Regulatory Affairs and Quality System Consultant, Makromed, Inc.

Jo Lee, M.Ec.

Founder, Somebusiness, Inc.,

Hao Howard Li, Ph.D. MBA

Cambridge Site Head, Novartis Knowledge Center, Novartis

Jing Jeannie Li, Ph.D.

Senior Scientist, Pfizer

Carrie Liu, Ph.D.

Associate Director of Analytical Chemistry, Concert Pharmaceuticals

Sue Ma, M.D.

Scientist II, Novartis Virology

Xue Shui, M.Sc.

Senior Research Associate, Dicerna Pharmaceuticals

Yueming Wang, MBA

Chairman & General Manager, Zhonguan Pharmaceutical Co. Ltd., Beijing, China

Zhigang Wang, Ph.D.

Sr. Principal Scientist, Celgene Avilomics Research

Li Xing, Ph.D.

Senior Principal Scientist, Pfizer

Wendy Yang, MBA

Manager, Business Management, Sanofi

Chunxiao Yu, Ph.D.

Post-Doctoral Fellow, Harvard Medical School, Boston, MA

Jingzhong Zhang, Ph.D.

Senior Scientist, Medica Corp

Wei Zhang, Ph.D.

Staff Scientist, Siemens Healthcare Diagnostics

Xiaoyong Zhao, Ph.D.

Senior Scientist, Momenta, Cambridge, MA

Shujia Daniel Dai, Ph.D.

Principal Research Investigator, Sanofi US, Cambridge, MA

Youxin Zhang, Ph.D.

Managing Consultant, Navigant Consulting

Board of Directors

Zhihong Chen, Ph.D.

CABA President (2011-2012)

Chaoyang Dai, Ph.D.

CABA President (2010-2011) Director, Business Development, Frontage

Jun Han, Ph.D.; Founding President

CEO, SOTA International LLC

Susan Qu, Ph.D. MBA

External Manufacturing Integrated Risk Manager, Sanofi

Lixin Shen, Ph.D.

President and CEO, Wuxi Howfond Biopharma Co., Ltd.

Zhao-Kui Wan, Ph.D.

CABA President (2009-2010) Head of Chemistry, Janssen Pharmaceutical Companies of Johnson & Johnson, Shanghai

Yihan Wang, Ph.D.

President, Shenzhen TargetRx, Inc., Shenzhen, China

Erxi Wu, Ph.D.

Associate Professor, Texas A & M University Health Science Center, TX

Junjun Wu, Ph.D.

CABA President (2007-2009) CEO, WuXi AllNature Biotech LLC,

Xiang Yang Yu, Ph.D.

CABA President (2013-2014) Program Manager, Accellent Partners LLC

Zhiyong Yang, Ph.D.

CABA President (2014-2015) Senior Principal Scientist, Pfizer

Philip Zhang, Ph.D., J. D.

CABA President (2012-2013) Co-Founder and Chairman, Milstein Zhang & Wu LLC

Legal Counsel

Fred Gilman

Attorney at Law, Lynch, DeSimone & Nysten, LLP

CABA Advisors

Youssef Bennani, Ph.D.

Site Head, Vertex Pharmaceuticals Inc. Canada

Tim Clackson, Ph.D.

President of Research and Development and Chief Scientific Officer, Ariad Pharmaceuticals Inc.

Yuan-Hua Ding, Ph.D.

Senior Director & Head of External R&D Innovation - Asia, Pfizer

Pierre Dodion, M. D., MBA

Sr. VP, Corporate Development, Ariad Pharmaceuticals Inc.

Chen Li, Ph.D.

Chief Executive Officer, Hua Medicine, Inc., Shanghai, China

Luke Li, Ph.D.

Exec Director, Head of Global Biotherapeutic Technologies, Bio-Innovation, Pfizer

Shi Li, Ph.D.

CEO, Zerun Biotechnology, Shanghai, CHINA

Yuanli Liu, Ph.D.

Director of China Initiative, Sr. Lecturer on International Health, Dept. of Global Health and Population, Harvard School of Public Health

Dawei Ma, Ph.D.

Professor, Shanghai Institute of Organic Chemistry, Shanghai

Tarek Mansour, Ph.D.

EVP of Research & Development, Xenon Pharmaceuticals Inc., Vancouver, Canada

Tse Ping

Chairman, Sino Biopharmaceutical Ltd., Beijing, China

Steve Projan, Ph.D.

Sr. V.P. R&D, Innovative Medicines Head of Infectious Diseases & Vaccines, MedImmune, Gaithersburg, MD

John Piwinski, Ph.D.

Principal, JJ Piwinski Pharma Consulting, LLC, New York

Tomi Sawyer, Ph.D.

Distinguished Scientist, Peptide Drug Discovery & Innovative Technologies, Merck Research Laboratories

Liming Shao, Ph.D.

Professor, Fudan University, Shanghai, China

Suvit Thaisrivongs, Ph.D.

Vice President, Pfizer, Inc., Cambridge, MA

Roger Tung, Ph.D.

CEO and President, Concert Pharmaceuticals, Lexington, MA

Yibin Xiang, Ph.D.

CSO, Sanhome Pharma

Gangfeng Xu, Ph.D.

Divisional Vice President, Corporate Licensing & Acquisitions at Abbott Laboratories

Steve Yang, Ph.D.

Executive VP & COO, Wuxi Apptec

Howard Yuwen, Ph.D.

Co-founder & VP Corporate Development & Regulatory Affairs, Genesun Pharmaceuticals

Zhaohui Sunny Zhou, Ph.D.

Associate Professor, Department of Chemistry and Chemical Biology and Faculty Fellow, Barnett Institute of Chemical and Biological Analysis, Northeastern University

CABA thanks the dedicated service from the 2 retired EC members:

Ze Tian, Ph.D.,

Anderson Cancer Center, Houston, TX

Jinbo Lee, Ph.D.

Co-founder and CSO, Scilligence Corporation, Burlington, MA



Chinese-American BioMedical Association

美中生物医药协会



CABA Mission Statement

- To promote science, technology, and business collaboration in biotech/pharmaceutical industry;
- To build and maintain a platform through cohesive scientific, professional, and cultural connection that provides high quality services;
- To facilitate networking among scientists, professionals, and entrepreneurs in academia, biotech/pharmaceutical industry and regulatory agencies;
- To embrace advancement of science and commercialization of innovation;
- To foster collaborations between the United States and China for the development of better biotech/pharmaceutical therapeutics.

About CABA

CABA is a 501(C)(3) not-for-profit professional organization registered in Massachusetts since May 2007. CABA is committed to promote public awareness of advancement in the pharmaceutical and biomedical industry, professional interactions in the fields of life sciences, global biomedical innovations and business development. As the majority of its members are scientists with Chinese heritage, CABA will operate in two important areas. One is to serve as a platform for its members to develop and advance their careers in the US pharmaceutical and biomedical industry, the other is to serve as a bridge to connect members including corporate members with the scientific and business resources in China thus facilitating collaboration between the pharmaceutical and biomedical industries across continents. To fulfill these goals, we will organize scientific and business symposia, conferences, workshops, in US and China, as well as social events to promote networking and communication among members. We will bring together members, scientists, professionals, government officials and business leaders across the continents under a collaborative environment and achieve their best potential. CABA is a volunteer based society. We rely on members to contribute their time and efforts to build the organization. We rely on corporate members and sponsors to raise fund to support the above activities. We value integrity, honesty, professionalism, community service, scientific excellence, responsibility and accountability. We invite you to explore our organization, and we are confident you will share our values and are interested in becoming a member, devoting your time or efforts, or sponsoring CABA activities. In summary, CABA is built by its members and serves its members.

Contact Us

If you have any comments, suggestions or feedback to our organization and our events, please feel free to contact us at cabaconnect@gmail.com. Your comments are important for us to improve in the future. Thank you very much!

Website: www.cabaweb.org

Email: cabaconnect@gmail.com

P.O. Box 426157
Cambridge, MA 02142



Notes

2016

BostonBioForum CABA Annual Conference



9:00 am to 9:00 pm, Saturday, April 30th, 2016
Sanofi, 153 2nd Ave, Waltham, MA 02451